Author

A. Chinnaiyan

h-index 173 View on Semantic Scholar

We have 6 of 1,217 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Aug 2026

Tumor-adjacent B cell infiltration stratifies recurrence risk in localized prostate cancer

Background: Biochemical recurrence (BCR) occurs in 20-40% of men after radical prostatectomy. Existing postoperative recurrence risk tools based on PSA and pathology are clinically useful but show only moderate and variable discrimination, highlighting the need for biomarkers that improve risk stratification and conseq...

B. Wang, S. Mukherjee, A. Baj et al. · medRxiv · 0 citations

Open access Sep 2026

Disentangling the cellular composition of FLCN-mutated tumors in Birt-Hogg-Dubé Syndrome by spatial transcriptomics.

Birt-Hogg-Dubé (BHD) syndrome is a hereditary cancer predisposition syndrome caused by pathogenic variants in the folliculin (FLCN) gene and is associated with an increased risk of multifocal renal tumors. FLCN-mutated tumors (FMTs) often exhibit morphological heterogeneity with mixed morphological features resembling...

Xiao-Ming Wang, Yu-Ping Zhang, R. Mannan et al. · Modern Pathology · 0 citations

Open access Sep 2026

Single-Atom Modification Enables Reversal of Degradation Selectivity between NSD2 and GSPT1

These findings demonstrate that minimal structural alteration permits precision control over degrader target selectivity, while furnishing selective chemical probes for NSD2 and GSPT1.

Wei-Zhong Shen, Yi-Han Liu, Lian-Chao Liu et al. · bioRxiv · 0 citations

Open access Sep 2026

Molecular Editing in Protein Degradation: From a Dual NSD2/GSPT1 Degrader to an NSD2-Selective PROTAC and a GSPT1-Selective Molecular Glue

Molecular editing, rooted in synthetic chemistry, has emerged as a powerful tool for structure optimization in medicinal chemistry but remains underutilized in targeted protein degradation. Here, we demonstrate the utility of molecular editing by repurposing the NSD2 degrader LLC0424 with GSPT1 neosubstrate engagement...

Wei-Zhong Shen, Yi-Han Liu, Lian-Chao Liu et al. · bioRxiv · 0 citations

Open access Aug 2026

Combined BET bromodomain and DNA methyltransferase inhibition targets critical survival pathways in transdifferentiated prostate cancer

Combined BET bromodomain and DNA methyltransferase (DNMT) inhibition was more effective than single-agent treatment in suppressing growth of TP53/RB1-loss models exhibiting a stem-like or NEPC program.

W. Storck, Diana Flores, A. Kumaraswamy et al. · JCI Insight · 0 citations

Open access Aug 2026

A Stress-Adaptive Lipid Kinase Axis Defines Metabolic Vulnerabilities in Neuroendocrine Prostate Cancer

Findings reveal a metabolic adaptation in NEPC and provide preclinical evidence that co-targeting PIKfyve and FASN can overcome hypoxia-associated stress adaptation.

Yang Zheng, Caleb Cheng, Yizhi Cao et al. · Cancer Cell · 0 citations